Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Subcell Biochem. 2022;98:205-221. doi: 10.1007/978-3-030-94004-1_11.
Macropinocytosis is a critical route of nutrient acquisition in pancreatic cancer cells. Constitutive macropinocytosis is promoted by mutant KRAS, which activates the PI3Kα lipid kinase and RAC1, to drive membrane ruffling, macropinosome uptake and processing. However, our recent study on the KRAS mutant indicated the presence of a KRAS-independent mode of macropinocytosis in pancreatic cancer cell lines, thereby increasing the complexity of this process. We found that KRAS-mutant cell lines promote macropinocytosis independent of KRAS activity using PI3Kγ and RAC1, highlighting the convergence of regulation on RAC signaling. While macropinocytosis has been proposed to be a therapeutic target for the treatment of pancreatic cancer, our studies have underscored how little we understand about the activation and regulation of this metabolic process. Therefore, this review seeks to highlight the differences in macropinocytosis regulation in the two cellular subtypes while also highlighting the features that make the KRAS mutant atypical.
巨胞饮作用是胰腺癌细胞获取营养的关键途径。组成性巨胞饮作用受突变型 KRAS 促进,该蛋白激活 PI3Kα 脂质激酶和 RAC1,从而驱动细胞膜皱襞形成、巨胞饮体摄取和加工。然而,我们最近对 KRAS 突变体的研究表明,胰腺癌细胞系中存在一种 KRAS 非依赖性的巨胞饮作用模式,从而增加了这一过程的复杂性。我们发现,KRAS 突变细胞系通过 PI3Kγ 和 RAC1 促进巨胞饮作用,而不依赖 KRAS 活性,这突出了调节作用在 RAC 信号上的收敛。虽然巨胞饮作用已被提议作为治疗胰腺癌的治疗靶点,但我们的研究强调了我们对这一代谢过程的激活和调节知之甚少。因此,本综述旨在突出两种细胞亚型中巨胞饮作用调节的差异,同时突出使 KRAS 突变体非典型的特征。